World

Polls close in key battleground states

Nov 06, 2024

Washington [US], November 6: As of 21:00 EST (02:00 GMT), polls have closed in 15 additional states, including critical battlegrounds Arizona, Michigan, and Wisconsin.
While projections have been made for more than a dozen states so far, it remains too early to gauge how these results might shape the final outcome of the presidential race.
Beyond the presidential contest, several pivotal Senate races and abortion-related ballot measures are drawing attention.
In Nebraska, Republican Senator Deb Fischer is facing a serious challenge from independent candidate Dan Osborn, a union mechanic and veteran who served in both the US Navy and National Guard.
Arizona's races are also worth following. Trump-backed Republican Kari Lake is vying for a Senate seat against progressive Representative Ruben Gallego.
The seat was previously held by Kyrsten Sinema, an independent who chose not to seek re-election.
On the topic of abortion, Arizona voters will decide whether to amend the state constitution to extend the right to the procedure from 15 weeks to around 24 weeks, or fetal viability.
Meanwhile, Nebraska will weigh two opposing abortion measures: one seeking to enshrine a right to abortion until fetal viability, and another aiming to uphold the state's current 12-week abortion ban.
Source: Fijian Broadcasting Corporation

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025